2mo
Disease Spotlight
Agitation in Alzheimer's Dementia
1mo
Pharmacological management of agitation in dementia: An evidence-based review with expert consensus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41527161/
Agitation is a frequently occurring and challenging neuropsychiatric symptom of Alzheimer's disease (AD) that substantially affects quality of life, caregiver burden, and healthcare utilization. Non-pharmacological interventions, especially trigger identification, environmental...
Evidence-based consensus reviews pharmacologic management of agitation in Alzheimer’s disease, emphasizing nonpharmacologic first-line care, cautious short-term medication use, brexpiprazole preference, and safety-driven selection of antipsychotics and antidepressants.
2mo
Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41521126/
Inflammatory and neuronal injury biomarkers may have prognostic value and may potentially inform treatment response and remission outcomes in apathy. Apathy in Dementia Methylphenidate Trial 2 (ADMET2), NCT02346201, https://clinicaltrials.gov/study/NCT02346201.
Secondary analysis of ADMET2 identifies inflammatory and neuronal injury biomarkers associated with apathy severity and methylphenidate response in Alzheimer’s disease, supporting biomarker-informed stratification of neuropsychiatric symptom management.
2mo
Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41439450/
PurposeAgitation is a neuropsychiatric symptom commonly observed in Alzheimer's dementia, which causes substantial burden for patients and caregivers. In this exploratory analysis, Neuropsychiatric Inventory (NPI) data were pooled from two...
Pooled analysis shows brexpiprazole significantly improved agitation, aggression, and other neuropsychiatric symptoms in Alzheimer’s dementia, with reduced caregiver distress, versus placebo across 12-week randomized controlled trials.
2mo
Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41358629/
BackgroundAgitation in Alzheimer's disease significantly impacts patient outcomes and caregiver burden. Brexpiprazole has emerged as a promising treatment option, but optimal dosing remains unclear.ObjectiveTo evaluate the comparative efficacy and safety...
Network meta-analysis shows brexpiprazole improves agitation outcomes in Alzheimer’s disease, with 2 mg offering optimal balance between efficacy and tolerability, while higher doses increase adverse events without added serious safety risk.